Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

BACKGROUND: Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpes simplex virus type-1 (HSV-1), is approved for patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohaan, Maartje W., Stahlie, Emma H. A., Franke, Viola, Zijlker, Lisanne P., Wilgenhof, Sofie, van der Noort, Vincent, van Akkooi, Alexander C. J., Haanen, John B. A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351098/
https://www.ncbi.nlm.nih.gov/pubmed/35927710
http://dx.doi.org/10.1186/s12885-022-09896-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351098/
https://www.ncbi.nlm.nih.gov/pubmed/35927710
http://dx.doi.org/10.1186/s12885-022-09896-4

Ejemplares similares